<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82AC974D-4565-4BCE-A841-D5259A9B6D0D"><gtr:id>82AC974D-4565-4BCE-A841-D5259A9B6D0D</gtr:id><gtr:name>Sealife Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37E19127-58AE-4048-8C12-1A28A61B9B59"><gtr:id>37E19127-58AE-4048-8C12-1A28A61B9B59</gtr:id><gtr:name>Adaptimmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D254125-0806-40E3-A97A-5D9D03D447D7"><gtr:id>9D254125-0806-40E3-A97A-5D9D03D447D7</gtr:id><gtr:name>AIDS Clinical Trials Group (ACTG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82AC974D-4565-4BCE-A841-D5259A9B6D0D"><gtr:id>82AC974D-4565-4BCE-A841-D5259A9B6D0D</gtr:id><gtr:name>Sealife Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37E19127-58AE-4048-8C12-1A28A61B9B59"><gtr:id>37E19127-58AE-4048-8C12-1A28A61B9B59</gtr:id><gtr:name>Adaptimmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D254125-0806-40E3-A97A-5D9D03D447D7"><gtr:id>9D254125-0806-40E3-A97A-5D9D03D447D7</gtr:id><gtr:name>AIDS Clinical Trials Group (ACTG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/39A367CA-12EE-4913-85A1-7C27976C496B"><gtr:id>39A367CA-12EE-4913-85A1-7C27976C496B</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Buchan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12020"><gtr:id>7A01FDE0-7908-4119-8AA8-B27019B9E0CA</gtr:id><gtr:title>Confidence in Concept 2012 - University of Oxford</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12020</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>750000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Professor Matthew Wood: Development of exon skipping therapy for Duchenne muscular dystrophy</gtr:description><gtr:id>D892AFC5-6403-4F9D-ACA0-703BE41E44F2</gtr:id><gtr:impact>Further progress: This work is likely to lead to publications in high impact, peer-reviewed journals, patents of resulting technology/candidate drugs for inducing skipping of exons 45-55 in DMD patients, leading to options for co-development with industrial partners in the future. This success will allow an application for a translational award to the Medical Research Council or the Wellcome Trust to further develop a generalized multiexon skipping targeting the whole exons 45-55 region of the human DMD gene which could enable the treatment of a large proportion of DMD boys.
IP: N/A
Further funding: Following this work, we have been successfully awarded a grant from Muscular Dystrophy Ireland in 2014 for ?20,000.
Uptake and translation: We anticipate interest from drug companies in this new technology and anticipate our exon skipping therapeutic agents will receive regulatory approval for use in DMD in the near future.</gtr:impact><gtr:outcomeId>sD7Ssi5y25w-1</gtr:outcomeId><gtr:partnerContribution>To identify the minimum combinatorial requirements for multi-exon skipping AO therapy for DMD</gtr:partnerContribution><gtr:piContribution>The aim of this project was to identify the minimum combinatorial requirements for multi-exon skipping oligonucleotides therapy for Duchenne muscular dystrophy (DMD). The long-term goal of this project is to combine this approach with the second generation peptide conjugated oligonucleotides that are currently being developed with Wellcome Trust Health Innovation Challenge Fund support, in order to develop a high efficiency generalised exon skipping approach to treat all DMD patients.
We found that minimal spontaneous exons 45-55 skipping of the Dmd gene at low frequency in mouse C2C12 myotubes, which can be explained by the order and the timing of dystrophin intron removal. Secondly, we confirmed the minimum combinatorial requirements using three oligonucleotides which can enhance exon 45-55 skipping in mouse C2C12 myotubes. Thirdly, we started a new collaboration with Dr. Yokota's group, Alberta University, Canada. We are testing the efficacy of exon 45-55 skipping using sequences of oligonucleotides in human rhabdomyosarcoma cell lines and human primary myoblast cells.We are going to synthesize peptide conjugated oligonucleotides with optimized sequences and test their efficacy in human DMD primary myoblast cells carrying exon 46-51 deletions.
The novelty of this work is to develop a multi-exon skipping oligonucleotides therapy for DMD with the minimum combinatorial requirements of oligonucleotides. As a next step, we plan to combine this approach with the second generation peptide conjugated oligonucleotides and to develop a novel multi-exon skipping approach high efficiency for all DMD patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases (NDORMS)</gtr:department><gtr:description>Professor Andrew Carr: A novel biomimetic tissue engineering scaffold for soft tissue repair (BioPatch)</gtr:description><gtr:id>E07A174B-D801-46A9-BB86-D1EED79FA49F</gtr:id><gtr:impact>Further progress: The study of the migration of stem cells and tenocytes through laminated patches in vitro has been achieved. The additional effect of growth factors, platelet rich plasma and stem cells on tenocyte growth and differentiation have been characterised. Characterisation of the interaction between the material and tendon-derived cells throughout the degradation of the patch in vitro and in vivo is underway. Manufacturing facility upscale is underway. Testing of the effective of sterilisation on material properties is planned. Clean room manufacture and Phase I human clinical trial is also planned. 
IP: Two patents filed in September 2013. Examined in March 2014 without undue concern raised. 
Further funding: &amp;pound;40k awarded in June 2014 from the Oxford University Hospital's Innovation Challenge Competition. 
Uptake and translation: The Oxford BRC will upscale production within the University/NHS partnership and produce the implant in a clean room for human use. One this has been successfully achieved, a Phase II clinical trial is planned. Potential industry partner has approached to discuss licensing but currently the plan is to upscale manufacturing internally and progress to clinical trial without external investment.</gtr:impact><gtr:outcomeId>gbUjritX2j8-1</gtr:outcomeId><gtr:partnerContribution>Primary objective: refine the prototype soft tissue patch. Prove biocomplatibility and efficacy and test pre-clinically in vitro and in vivo.</gtr:partnerContribution><gtr:piContribution>Age related soft tissue degeneration and inflammation (tendon, muscle and cartilage) affects around 35% of the population causing significant pain, loss of function and time off work. Rates of shoulder surgery for tendinopathy and tendon tear have increased over the past ten years by around 750% in the USA and the UK. But, between 20% and 90% of tendon repairs fail within the first few months after surgery. This project has made significant progress to producing a safe, effective and cost effective tissue repair patch that can be used to enhance and improve the success of tendon repair surgery. A novel, degradable, woven and electrospun patch prototype has been developed, characterised and tested utilising in vitro tools and primary tendon-derived cells, showing exceptional biocompatibility, improved cell attachment and that cells could migrate across the patch towards a chemo-attractant. Proof of concept was achieved in vitro by (a) using human tendon-derived cells as a model system to evaluate the patch and (b) implantation in a tendon injury model in rats. Safety data was gathered in vitro and in vivo, including cytotoxicity, tissue reaction and implant integrity. The electro-spinning and weaving processes were enhanced to enable the production of laminated patches as well as improved homogeneity. The quality of the tendon-bone repair in the rat was carried out with and without the patch in terms of mechanical properties of the tendon to bone insertion has been assessed. There is a potential for using this scaffold in the surgical repair of interfaces such as the tendon insertion in the rotator cuff, in conjunction with growth factors and / or stem cells. (Hakimi et al 2012).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>Dr Rebecca Park: Hungry for reward: a translational study of brain processes underpinning Anorexia Nervosa</gtr:description><gtr:id>FE99CC21-A4E9-4B1B-B15A-5414B4611EDD</gtr:id><gtr:impact>Multimodal imaging data of AN including fMRI and MEG will be a unique data set and when combined with fMRI of major impact in the field. In collaboration with data analysis with Dr Mark Woolrich and Kia Nobre at OHBA -who have recently been awarded a programme grant to better develop and integrate multimodal imaging data- we are in an excellent position to lead on advancing understanding of neural basis of AN to aid treatment target development. Positive results from pioneering treatment development of DBS could thus be a game changing for the treatment of severe AN, potentially saving lives in addition to saving substantial sums of healthcare funding. Ethical considerations are however complex and of major importance, warranting ethical study in tandem.

Dr Park sent the future grant outline derived from this pilot MRC CIC data to head of neurosciences and head of mental health at the MRC and discussed it with them in June 2014. They are encouraging submission of a project grant to further this work and we expect to submit in January 2015. Co-applicant Professor Aziz has also applied to the Charles Wolfson Charitable Trust for a grant.

Medtronic have donated 3 stimulator systems of which one has been implanted and St. Judes have donated one for this study. Clinical translation is immediately apparent- as the DBS pilot study is registered on open access clinical trials. We have had enquiries and requests to participate from all over the UK, Europe (Germany) and the USA. At present we have ethical approval for 2 further cases but have not yet secured the funding.</gtr:impact><gtr:outcomeId>A6nCuUd5Xxe-1</gtr:outcomeId><gtr:partnerContribution>To investigate key brain areas involved in reward processing-hedonic appraisal (liking) incentive salience (wanting) and learning and their interaction with cognitive control process, in order to define optimal targets for effective intervention in severe AN</gtr:partnerContribution><gtr:piContribution>Severe longstanding Anorexia Nervosa has the highest mortality of any psychiatric disorder and is one of the most challenging and expensive to manage, with a major paucity of effective treatments. The broad aim of this project was to map the neural mechanisms underpinning aberrant reward in Anorexia Nervosa (AN), and to translate this understanding into the development of a novel neuroscience-based treatment. It combines an experimental strategy with complementary forms of cutting-edge neuroimaging including DTI, fMRI and MEG (studies 1-4). These will be augmentative in identifying optimal targets for intervention for severe AN using Deep Brain Stimulation (DBS) (study 5) on a single case. Analysis of resting state and task based fMRI data (studies 2 and 4) is underway. Preliminary findings of fMRI task and resting state data will be presented at the Eating Disorders Research Society in Sand Diego, October 2014. Study 5 is the first Pilot study of DBS for AN in the UK; the operation completed in April 2014 and now in data collection phase of psychiatric, neuropsychological and neuroimaging follow-up, and ethical sub-study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Professor Paul Klenerman: A novel therapeutic approach for Hepatitis B virus</gtr:description><gtr:id>901265F6-835F-4235-802F-C20247781457</gtr:id><gtr:impact>The RNAseq data analysis on HepaRG cells treated with Activin A will be completed to understand the impact of this compound on total RNA expression and compare it with the already obtained data from microarray analysis. This will help the understanding of the mechanism by which Activin A works as an antiviral. Further planned study includes the impact of Activin A which works as a better stimulator of innate response genes and significantly impacts upon HBV virions in cell culture. siRNA mediated inhibition of specific genes and/or CRISPR technology will be used to see if it affects the antiviral activity in the HepaRG cell line or other cell lines like the newly described Huh7 cells stably transfected with hNTCP (which we have established in the lab recently) is now known to act as a receptor for HBV and HDV.

Activin A shows promise as an effective antiviral against HBV infection in the cell culture model. As it triggers potent host cell antiviral pathways, there is great potential to take this further into potential therapy. However, more work is needed to identify the mechanism involved in this process and its specificity before such trials can be planned.</gtr:impact><gtr:outcomeId>gNyofHxQcH6-1</gtr:outcomeId><gtr:partnerContribution>To define the antiviral activity of BMP6 in vitro against HBV</gtr:partnerContribution><gtr:piContribution>Hepatitis B Virus (HBV) is a major cause of liver disease and cancer, affecting 300 million people. Treatments exist but are typically only partially effective. Progress has been made to develop a new treatment approach based on novel small molecules. The TGF-? family member BMP-6 has been tested for antiviral activity against HBV in a tissue culture system using the HepaRG hepatocyte cell line as a model for HBV infection. The related compound Activin A is a better inhibitor of HBV infection in cell culture systems. Genes involved in the TGF-? superfamily seem to be closely involved in triggering an antiviral response in hepatocytes infected with HBV. The specific pathway for this antiviral mechanism remains to be fully identified - both the signalling arm and the effector arm. However this project, involving qRT PCR and microarray analysis, show that innate immune response genes classically linked to the interferon pathway likely play a vital role and are being upregulated in response to Activin A. Activin A shows potential as a combined antiviral drug and can either complement or perhaps supplement IFNa or directly acting antivirals, both of which are imperfect therapies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Professor Dame Carol Robinson: A new way of exploring drug and lipid binding to membrane protein complexes</gtr:description><gtr:id>F67DD5F3-2F16-448E-80D9-F72CF95B8DEB</gtr:id><gtr:impact>Further Progress: This publication generated considerable interest from major pharma resulting in a number of key collaborations with Roche, Amgen and Genentech. 
IP: Two patents have been filed one previously protecting the idea to use this methodology for membrane protein drug discovery the other relating to the discovery of detergents that maintain the native state of the membrane protein such that unfolding can ensue.
Further Funding: The PI obtained a senior investigator award from the Wellcome Trust based on the proof of concept data form this project. The next steps from the CiC project represented one of the five streams of research proposed in the Wellcome Trust project. Funding to support this stream of work totals to date: WT &amp;pound;2.2million, Roche &amp;pound;25K, ONT &amp;pound;25K. 
Uptake and translation: The PI is has hosted a collaboration with an academic visitor from Roche studying membrane proteins and ligand binding using our unique approaches. Two other pharmaceutical companies are keen to explore the technology, one has requested an in-house example and is considering funding for personnel, the other have also organised a visitor to observe the experiment in action.</gtr:impact><gtr:outcomeId>rLGMMfuSZuC-1</gtr:outcomeId><gtr:partnerContribution>To exploit the use of ion mobility mass spectrometry for drug discovery by identifying new detergents for introducing membrane complexes into the gas phase</gtr:partnerContribution><gtr:piContribution>The aim of this project was to exploit the use of ion mobility mass spectrometry for drug discovery by identifying new detergents for introducing membrane complexes into the gas phase; to fine-tune our mass spectrometry approach to report on the effects of drug binding on membrane protein complex stability and folding; to contribute to the development of a robust method for assaying drug binding to membrane proteins. We were successful in expressing and purifying a number of membrane proteins using different protocols and different detergents optimized for mass spectrometry. We completed an investigating MS and solution conditions that preserve the complex as close to its native fold state as possible. This proved more challenging since many detergents perturb the native state of the protein. Lipidic environments for studying membrane proteins were employed - an important development for GPCRs which are often oligomeric in the presence of specific lipids. 
The gas phase unfolding method applied to membrane proteins is unique in the world and has enabled us to gain the first insights into lipid binding to membrane proteins. These developments were necessary to pave the way for the more difficult case of drug binding to membrane proteins. The novel methodology was reported in Nature this year and featured on the front cover of the journal. (Laganowsky et al Nature 510: 172, 2014).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Adaptimmune</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adaptimmune Ltd</gtr:description><gtr:id>F8D70ABC-EBD4-46AF-9A29-C132E92F2DE1</gtr:id><gtr:impact>MRC Confidence in Concept award - 2013
No publications as yet, although work in progress</gtr:impact><gtr:outcomeId>geVBjv68uyU-1</gtr:outcomeId><gtr:partnerContribution>Industry Partner Collaboration to provide reagents and services.
Services include mass spectrometry and T cell line preparation
Reagents include Adapted TCRs and viral vectors</gtr:partnerContribution><gtr:piContribution>Industry partner. Utilisation of partner's reagents and facilities to expand primary cell models of latency and proof-of-concept strategies for novel HIV interventions.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>Professor Sten Eirik Jacobsen: Therapeutic cycling and targeting of myelodysplastic syndrome stem cells</gtr:description><gtr:id>4E478C6D-D725-48FA-AAEB-F6B642DDF4F5</gtr:id><gtr:impact>We have an on-going collaboration with Dr Paal Holm, clinical lead in ITP at Rikshospitalet, University of Oslo, Norway, to study bone marrow samples from patients with ITP treated with Romiplostim.</gtr:impact><gtr:outcomeId>qAppnyBhsVT-1</gtr:outcomeId><gtr:partnerContribution>Impact of THPO mimetics on the cycling of normal HSCs</gtr:partnerContribution><gtr:piContribution>This project had two objectives: (1) to study the impact of thrombopoietin mimetics on the cycling of normal HSCs and (2) to investigate the effects of thrombopoietin mimetics on MDS stem cells.

Using state of the art in-vitro stem cell assays, we have established that Romiplostim cycles phenotypic human stem cells and enables enhanced elimination post chemotherapy. We are now performing experiments to establish the impact of Romiplostim to cycle and enhance elimination of functional stem cells. This should be completed by the end of the year.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Stephen G. Davies</gtr:description><gtr:id>359508B5-1723-4D4E-9BFD-C0880928C312</gtr:id><gtr:impact>-Estabishment of spin-off company OxStem Oncology</gtr:impact><gtr:outcomeId>56e16141249e55.97458837-1</gtr:outcomeId><gtr:partnerContribution>chemical libraries for targeting of MDS stem cells</gtr:partnerContribution><gtr:piContribution>Models and assays for cancer/MDS stem cell targeting</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Professor Katherine Vallis: Quantitative Autoradiography at Ultra-High Spatial Resolution: Demonstration of Applications</gtr:description><gtr:id>231888E2-CFFA-4690-BFA9-85AC92CEAC5E</gtr:id><gtr:impact>Further funding: We secured funding for an EPSRC studentship. The candidate, Georgina Royal has successfully defended her transfer and is now in her second year as a PhD student. Her thesis expands on the use of photoresists as a dosimetric tool for molecularly targeted radionuclide therapeutics. The proof of concept work funded within the CiC work will serve as the basis of an application for a programme grant for Dr. Nadia Falzone.
Uptake and translation: We had preliminary discussion with a pharmaceutical company regarding possible application of this technique to alpha-emitting radiopharmaceuticals.</gtr:impact><gtr:outcomeId>biGzRSsPb4C-1</gtr:outcomeId><gtr:partnerContribution>The overall aim is to strengthen the credentials of the method by demonstration of applications, and thereby secure funding for further development.</gtr:partnerContribution><gtr:piContribution>The central objective was to use ultra-high spatial resolution photoresists as autoradiography substrates to enable microdosimetric analyses of targeted radiotherapy agents. The initial motivation for this work was optimizing the detection of Auger electron-emitting radionuclides used for therapy, but the technique has since been extended in the detection of alpha-particles. Work underpinning the (1) cryo-tomography and enhanced spatial resolution and (2) correlating radionuclide distribution with DNA damage is still continuing with results to date recently presented at the Association of Radiation Research (ARR) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meetings. The method has been extended in the detection of alpha and the results have been published in two recent papers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Professor Adrian Hill and Dr Irina Redchenko: Pre-clinical efficacy evaluation of the novel vaccine for prostate cancer</gtr:description><gtr:id>435A9830-587F-416A-A877-96A52B122684</gtr:id><gtr:impact>Further Funding: EC project Improving Prostate Cancer Outcome with Vectored Vaccines (IMPROVE). The value is ?6M for 4 years across 5 European partners. The project includes funding for Phase I and Phase II clinical trials and further vaccine development to identify new vaccine targets and increase immunogenicity and efficacy. 
Uptake and translation: Phase I and II clinical trials have been funded. Potential collaborations with pharmaceutical companies in clinical development are underway.</gtr:impact><gtr:outcomeId>A4CLwJBXFH2-1</gtr:outcomeId><gtr:partnerContribution>Objective: to evaluate a novel vaccination strategy as an immunotherapy for prostate cancer</gtr:partnerContribution><gtr:piContribution>A vaccination platform based on a combination of two viral vectors encoding the same prostate cancer antigen has been studied to determine whether it can achieve cancer-protective immune response in a prostate cancer mouse model. Recombinant viral vectors, a simian adenovirus, ChAdOx1, and pox virus, MVA, expressing prostate-associated antigens PAP, PSCA, PSMA, STEAP1 and 5T4 have been constructed. The immunogenicity of those vectors delivered in a prime boost vaccination regime has been evaluated in the wild type C57BL/6 mice. The vaccine prophylactic and therapeutic efficacy has been tested in a tumour transplantation model. The vaccine therapeutic efficacy has been tested in in the transgenic adenocarcinoma of mouse prostate model (TRAMP).
A strong T cell immune response has been generated against one of the tested antigens following vaccination with the vectors encoding this antigen. The induced immune response has been modestly protective in wild type C57BL/6 mice and TRAMP mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Professor Mark Moloney: New generation antibacterial agents</gtr:description><gtr:id>E4782EC9-3A22-407C-AA4E-BDC3AE455206</gtr:id><gtr:impact>Further progress: A second CiC award has been given for this stream of activity. See CiC 26. 
IP: The data from this work will provide additional supporting data for two patents currently in prosecution. 
Further funding: MRC DPFS applied for (Sep 2014) and the results from this work will also be used to provide preliminary data for an MRC AMR Innovation Grant planned for January 2015. Support by this programme has assisted the establishment of Antibacterial Discovery-UK, a network of scientists interested in the development of next generation antibacterials, and able to offer contributing expertise. Currently in the process of being expanding globally. Funding for this network will be applied for from an MRC AR Theme 2 Grant.</gtr:impact><gtr:outcomeId>ALPxZ5z2Dfu-1</gtr:outcomeId><gtr:partnerContribution>To optimise in a three way simultaneous study, synthesis, phenotypic activity and plasma protein binding, in order to successfully achieve in vivo activity</gtr:partnerContribution><gtr:piContribution>Using natural products as inspiration, new series of chemical compounds have been synthesised and evaluated for their antibacterial activity, providing access to three structurally unprecedented classes of compounds which are active in vitro predominantly against Gram positive, but also some Gram negative, strains. This work has provided a good understanding of the structural basis for this activity, enabled the development of a pharmacophoric model, and established the mode of action, which is against the unusual target, UPPS; IP for this work has been secured. Some compounds are active against UPSS and RNAP, and this offers significant advantage for the design of potent inhibitors. Work is currently underway to obtain detailed protein-inhibitor structural information by crystallographic protein analysis (with OPPF). Critically, these systems have never used therapeutically and therefore have not been widely dispersed amongst human and animal populations, so resistance might be expected to evolve more slowly. The next stage, funded as part of the MRC CiC programme, was to optimise in a three way simultaneous study, synthesis, phenotypic activity and plasma protein binding. This funding opportunity was also used to scope an entirely novel antibacterial delivery strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Eva Hellstr&amp;ouml;m Lindberg</gtr:description><gtr:id>E03B5F17-438B-49AB-9A86-DDB26ED31A20</gtr:id><gtr:impact>Multiple high impact publications listed in outcome</gtr:impact><gtr:outcomeId>56e15e6f692576.15445627-1</gtr:outcomeId><gtr:partnerContribution>Clinical expert on MDS</gtr:partnerContribution><gtr:piContribution>Studies of MDS ste and progenitor cell biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Industrial collaboration</gtr:description><gtr:id>DE338B4D-1C72-4AC3-B1EA-7BF38AF20CC1</gtr:id><gtr:impact>No finalised outcomes yet</gtr:impact><gtr:outcomeId>56d46e079f0022.13021706-1</gtr:outcomeId><gtr:partnerContribution>Supply of bioassay and expertise</gtr:partnerContribution><gtr:piContribution>Supply of new chemical entities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Elli Papaemmanuil</gtr:description><gtr:id>619B5614-E9B7-4765-B4CE-C784CEC94351</gtr:id><gtr:impact>Key for publication Woll et al, Cancer Cell, 2014</gtr:impact><gtr:outcomeId>56e16067a4c6c5.77307442-1</gtr:outcomeId><gtr:partnerContribution>Expertise in exome sequencing</gtr:partnerContribution><gtr:piContribution>MDS stem cells for sequencing for targeted mutations</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Sten Linnarsson</gtr:description><gtr:id>E7048A66-0E50-4B30-997E-83E3A317C116</gtr:id><gtr:impact>Publications as listed above</gtr:impact><gtr:outcomeId>56e15fdee60d40.49523541-1</gtr:outcomeId><gtr:partnerContribution>Sten Linnarsson is a world leader in single cell RNA sequencing and his input has been key to several of our reported publications utilising small cell number or single cell RNA sequencing (Cell Stem Cell 2013; Cancer Cell 2014)</gtr:partnerContribution><gtr:piContribution>Single cell analysis of stem and progenitor cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Roche</gtr:description><gtr:id>9B2AE679-C18E-432A-AA76-E6D92949D9BE</gtr:id><gtr:impact>Invitation to visit F. Hoffmann-La Roche to give lecture and set up possible studentship.</gtr:impact><gtr:outcomeId>56d85d8f380180.21465149-1</gtr:outcomeId><gtr:partnerContribution>Contacts in industry</gtr:partnerContribution><gtr:piContribution>Hosting visitor to study membrane proteins and ligand binding using unique approaches developed in our laboratory</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Professor Quentin Sattentau: Immune refocusing for influenza vaccine development</gtr:description><gtr:id>7654175F-96A9-47D2-A30C-77E1739F99ED</gtr:id><gtr:impact>The project has (1) produced medium-scale quantities of soluble recombinant influenza HA, both wild-type and lysine modified, (2) verified that this glycoprotein is correctly folded and binds neutralizing antibodies directed to HA1 and HA2, (3) quantitatively adducted the SiaLac immune masking agent to the HA and achieved ~100% lysine occupancy and (4) immunized mice and demonstrated similar immunogenicity of both wild type and SiaLac-modified antigens. The immune silencing agent, SiaLac, was found to be immunogenic, and diverted a major proportion of the antibody response to SiaLac. This prevented the goal of shifting immune dominance towards conserved neutralization epitopes on the protein surface from being achieved.

Since the project was highly successful with the exception of the unexpected immunogenicity of the SiaLac glycans, we intend to repeat the epitope masking using other immune silencing agents. At present we are investigating other types of sugar (polymerised sialic acid, mannose groups) and polymer (polyethylene glycol) for their silencing properties and will then link these to the lysine groups on the modified HA.</gtr:impact><gtr:outcomeId>QyHfHgVFyUt-1</gtr:outcomeId><gtr:partnerContribution>.</gtr:partnerContribution><gtr:piContribution>The aim of this project was design a universal influenza vaccine antigen that elicits antibodies that neutralize a broad spectrum of influenza A strains using novel 'glycan-masking' technology. This technology relies upon post-translational linking of immune-masking semi-synthetic glycans to specific residues (in this case lysines) on the protein surface, allowing site-directed silencing of variable antibody epitopes and re-targeting of the antibody response to conserved neutralization epitopes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>Dr Tudor Fulga: Rewiring cellular behaviour using miRNA-responsive synthetic devices</gtr:description><gtr:id>40AAD7AB-4C9A-4BB8-98B3-C9D42A6AB6EA</gtr:id><gtr:impact>We have established a strategic collaboration with the company Eukarys SAS in order to make use of their patented C3P3 technology, consisting of a chimeric enzyme capable of producing capped mRNA transcripts from a cytoplasmic plasmid. Discussions with ISIS innovation were promising and they indicated a desire to patent this work. The recommendation is however that we consider patent application only immediately before publication. 

The next step in this project will involve coupling allosteric ribozyme activity to an output apoptotic response. This will be facilitated both by the generation of new allosteric ribozymes demonstrating superior ON:OFF rates (from our in vitro evolution experiments) as well as the rational tuning of pro-apoptotic proteins by mutagenesis. Once validated, these circuits will be tested in a cell culture model of EBV infection to demonstrate their ability to detect specific EBV miRNA inputs and in response activate the apoptotic pathway. In order to construct circuits of higher complexity we plan to multiplex allosteric ribozymes, responsive to different input miRNAs into the 3' UTR of a single output protein. In addition to the theoretically enhanced ON:OFF rate, these multi-input logic gates should be capable of detecting the subtle alterations in miRNA expression levels often associated with human disease such as cancer, therefore making them susceptible to specific targeting using our devices.</gtr:impact><gtr:outcomeId>mwm2Yd62yTB-1</gtr:outcomeId><gtr:partnerContribution>Optimise the ON:OFF ratio of a prototype miRNA-responsive device</gtr:partnerContribution><gtr:piContribution>Cellular reprogramming using synthetic gene networks offers much promise for advancing scientific and therapeutic innovation. MicroRNA expression patterns provide a unique signature differentiating cells based on type as well as physiological state (including disease state) and could form an ideal input for such systems. To test this concept, we have constructed a prototype ribozyme-based controller containing a sensor/actuator and effector module, which can couple miRNA activity with the induction of GFP expression. Our preliminary experiments revealed that such a synthetic classifier could be activated in mammalian cells and in principle its activity can be modulated in the presence or absence of a specific input miRNA. We propose to expand this conceptual framework and showcase the potential of these logic function classifiers to enable user-regulated actuation of cellular behaviour. Ultimately, we plan to apply this strategy to engineer a prototype miRNA-responsive device for the detection of virally infected cells based on the digital presence or absence of exogenous viral miRNAs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Industry Visitor</gtr:description><gtr:id>5573F906-E4B4-414C-9BC0-C8AA87B7D540</gtr:id><gtr:impact>Invitation to speak at Amgen</gtr:impact><gtr:outcomeId>56d86022e15799.96689991-1</gtr:outcomeId><gtr:partnerContribution>Contacts in industry</gtr:partnerContribution><gtr:piContribution>Study of membrane proteins and ligand binding using approaches developed in laboratory.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sealife Pharma</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Antibacterial bioassays</gtr:description><gtr:id>6E1D19B4-B465-4D47-A372-CDAFD682F5DB</gtr:id><gtr:impact>Data not finalised yet</gtr:impact><gtr:outcomeId>56d46e6af3ba76.16484099-1</gtr:outcomeId><gtr:partnerContribution>Supply of antibacterial bioassays</gtr:partnerContribution><gtr:piContribution>Supply of new chemical entities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Dr Radu Aricescu: A novel diagnostic method for autoimmune disorders based on cell-derived vesicle microarrays</gtr:description><gtr:id>795AE852-4CCE-486F-9B28-BE4E235A364A</gtr:id><gtr:impact>Vesicle production from Aquaporin-4 (AQ4) transfected HEK cells has been improved and relative large preparations of membrane vesicles produced, suitable for 100-200 assays. 

Immuno-assay with AQ4 vesicles were optimised allowing blind screening of 100 patient sera and controls with very good correlation with diagnostic cell-based assay (major project goal achieved). Myelin Oligodendrocyte Glycoprotein (MOG) vesicle is in production for use in immuno-assay with MOG vesicles. Cloning of other neuronal receptor targets for use in the vesicle immuno-assays is on-going. Construction and validation of &amp;quot;AviFlag&amp;quot; tagging for binding to streptavidin was achieved (major project goal achieved) and we are establishing use of vesicles in a Streptavidin-coated micro-array system.

A patent was filed in June 2014. The CiC project funding was used to successfully demonstrate exemplification of concept that has been included in the filing. Project will be launched to coincide with publication paper.</gtr:impact><gtr:outcomeId>Tu2ebUYfhuG-1</gtr:outcomeId><gtr:partnerContribution>.</gtr:partnerContribution><gtr:piContribution>The aim of this project was to (1) Establish an efficient, reproducible and easy to scale-up procedure to generate cell-membrane derived outside-out vesicle preparations stable for long-term storage at 4C or, if possible, even dried, (2) Demonstrate that such vesicles are suitable for detection of autoantibodies in routine diagnostics. This will build on our successful preliminary work on AQP4 (shown below) and include known autoimmune targets such as glutamate, GABAB and glycine receptors, as well as other surface proteins (LGI1, CASPR2) and (3) Develop a procedure to improve immobilization of the vesicles displaying proteins of interest, using in-vivo biotinylation and streptavidin-coated slides or other substrates (i.e. membranes for potential dip-stick development).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Paresh Vyas</gtr:description><gtr:id>02BC81EB-AF5C-4C7B-92AB-D948F7F794C6</gtr:id><gtr:impact>Several publications including Goardon et al, Cancer Cell 2010; Tehranchi et al, NEJM 2010; Woll et al, Cancer Cell 2014</gtr:impact><gtr:outcomeId>56e15d362d51a1.56525722-1</gtr:outcomeId><gtr:partnerContribution>Clinical expertise in MDS and AML</gtr:partnerContribution><gtr:piContribution>Mouse models of MDS and malignant hematopoiesis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Professor Christopher Schofield: Potential for Translational Effects of BBOX Inhibition</gtr:description><gtr:id>192D8F7E-3A3F-4641-B621-E3F7DAB4DDE5</gtr:id><gtr:impact>Further progress: The funding has enabled multiple publications and a potent application. In an unexpected development the screening methods developed were also applied to an antibiotic resistance enzyme. The resultant publication Angewandte Chemie Int. Ed., 2014, 53(12), 3129-3133 made the front cover of Angewandte Chemie, has attracted considerable attention. 
IP: A patent has been filed.
Further funding: Preliminary results and information from this project was the basis of a successful BBSRC grant value &amp;pound;660k to characterise carnitine biosynthesis enzymes and make inhibitors. 
Uptake and translation: The work enabled the development of assays that have been used in the development and predicting of selective oxygenase inhibitors. The work has helped to enable an IMI project on screening for inhibitors of a human oxygenase. We are also collaborating with a major pharmaceutical company on aspects of the work.</gtr:impact><gtr:outcomeId>Dp3TRUYhLq3-1</gtr:outcomeId><gtr:partnerContribution>Objective: to identify potent and selective inhibitors for BBOX</gtr:partnerContribution><gtr:piContribution>BBOX is a 2OG-dependent oxygenase that catalyses the final step in the biosynthesis of carnitine from Ne-trimethyllysine in animals. Carnitine if important in fatty acid metabolism, enabling transport of fatty acids in mitochondria. There is evidence that BBOX is a viable target for small molecule inhibition for the treatment of cardiovascular disease. In this project selective BBOX inhibitors were identified, assays suitable for HTS and cell-based screens were optimised, the solution of crystal structures of BBOX-inhibitor complexes revealed unprecedented mechanism of action</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Irene Roberts</gtr:description><gtr:id>D44B4FE6-C5A2-4F94-846A-79C53B4A601F</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>56e15dbb869756.09113381-1</gtr:outcomeId><gtr:partnerContribution>-</gtr:partnerContribution><gtr:piContribution>-</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Claus Nerlov</gtr:description><gtr:id>7FA48C4B-85D5-47A6-BC58-B922847260B1</gtr:id><gtr:impact>As listed in outcome multiple high impact joint publications</gtr:impact><gtr:outcomeId>56e15cc8390437.40710254-1</gtr:outcomeId><gtr:partnerContribution>Mouse genetic models of normal and malignant hematopoiesis</gtr:partnerContribution><gtr:piContribution>stem and progenitor cell characterisation</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Dr John Frater: Curing HIV: Immune Targeting of the Latently-Infected Cell</gtr:description><gtr:id>40CF68BB-7550-4AE1-BEF2-683CAF1387F5</gtr:id><gtr:impact>Further funding: An MRC Senior Fellowship to the PI, &amp;pound;1.78M has been awarded partly as a result of the preliminary data gained from the CiC award, and a Commonwealth Studentship has been awarded to allow a new DPhil to take the work on from next term. An MRC Developmental Clinical Study Award has been awarded to the CoI for a proof of concept trial towards a Cure for HIV for &amp;pound;1.99M.
Uptake and translation: Results too preliminary for take up with industry beyond current engagement with Adaptimmune Ltd. The principle of immune targeting of the HIV reservoir has achieved clinical translation in the form of a randomised study of HDAC inhibitors plus vaccination commencing recruitment in 1st Quarter 2015 (MRC DCS award), the principles of which are guided by those in this award and on which the PI on this CiC award is a co-PI. Work continues in applying affinity adapted T cell receptors to HIV-infected target cells and further characterisation through Mass Spec and fluorescent microscopy.</gtr:impact><gtr:outcomeId>U6o1YtoC4Kc-1</gtr:outcomeId><gtr:partnerContribution>Objective: to assess the viral proteins both produced within the cell and expressed on the cell surface using MALDI-TOF mass assymetry,</gtr:partnerContribution><gtr:piContribution>Our aim was (1) to assess the viral proteins both produced within the cell and expressed on the cell surface using MALDI-TOF-TOF mass spectrometry (2) to demonstrate recognition and killing of latently-infected cells using highly specific T cell receptors (TCRs) transduced into cytotoxic T cells and (3) to use soluble TCRs conjugated to fluorochromes to identify specific antigens present on the surface of latent cells using fluorescence microscopy.
The objectives have been met in part, with some proof of principle data for all three, but of varying stages. The delay has been essentially due to the interest of a pharmaceutical company in the same reagents that our industry partner was donating to us. However for the three objectives (1) Enough cells of the 8E5 cell line which models HIV latency could be grown to allow mass spec analyses in the absence and presence of cellular activation. Preliminary evidence indicated that HIV peptides were being presented in this latent cell line. The next step is to enhance the peptide elution stage. (2) It was possible to transduce the T cell receptor into CD8+ve T cells and to transduce HLA A2 into target cells. We then have been able to show enhanced killing. Interestingly the drugs under investigation for use in HIV trials (HDAC inhibitors) resulted in decreased killing and we are currently investigating the extent to which HLA Class I is down-regulated. (3) We have changed the detection technique from microscopy to flow cytometry to enhance sensitivity.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>CHERUB Cooperative: Collaborative HIV Eradication of Reservoirs: UK BRC</gtr:description><gtr:id>5DCE61D3-41A5-4A1A-9CC8-A010FA405353</gtr:id><gtr:impact>Initially funding from the NIHR CBRC renewal across all five CBRCS</gtr:impact><gtr:outcomeId>GPMM2J4LpoC-1</gtr:outcomeId><gtr:partnerContribution>Academic, strategy and intellectual input</gtr:partnerContribution><gtr:piContribution>I am the chair of the CHERUB TSC, the scientific lead and overall co-PI. CHERUB infrastructure has been funded across all five CBRCs as part of a 5-way cooperative agreement</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Ben Davis - biological chemistry</gtr:description><gtr:id>0C1FC6DF-7E9A-4C05-942F-FB61CDD107A6</gtr:id><gtr:impact>The Davis group has helped us develop a chemical cross-linking protocol for improving vaccine antigen stability

The Davis group has piloted the site-specific adduction of reactive carbonyl groups to peptides and proteins</gtr:impact><gtr:outcomeId>56d074d9bb00b6.38379267-1</gtr:outcomeId><gtr:partnerContribution>The Ben Davis group in Chemistry has been designing reactive synthetic glycans for conjugation to immunogens including influenza HA that we are using for immunological studies

The Davis group enables us to adduct reactive carbonyls in a site-specific manner to peptides, and we are investigating this for use in proteins for the current BBSRC-funded project</gtr:partnerContribution><gtr:piContribution>We have designed projects in which synthetic glycans are used to mask surfaces of vaccine immunogens to re-focus their immunogenicity. We provide the designs and the protein to which the glycan are linked, then we carry out the immunological analysis.

We have provided peptide sequences to which we wish to adduct reactive carbonyls, allowing us to test proof-of-concept for the immune activatingn properties of these peptides. The Davis group has carried out the modified peptide synthesis and quality control.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Dr Ruth Muschel: Hedgehog Signalling as a Biomarker for Prostate Cancer Prognosis</gtr:description><gtr:id>887313CF-072D-4B4F-B95C-CABA70500793</gtr:id><gtr:impact>From these studies, it may eventually be possible to organize the most promising cancer markers into an expression array that could be useful as a predictive tool, or signature, for cancer aggressiveness. Thus, if Hh proves to be an important factor in prostate cancer severity, inhibitors against the pathway may be conducted. The use of anti-Hh drug adjuvant to radiotherapy is of particular interest.

If Hh proves to be prognostic for prostate cancer severity, and laboratory inhibitors efficacious against the pathway, a clinical trial may proceed. In addition, the use of anti-Hh drug adjuvant to other chemotherapies or to radiotherapy would be of interest.

Intellectual property: The The OX-TMA is the property of the University of Oxford.</gtr:impact><gtr:outcomeId>MqnQRgJWcQA-1</gtr:outcomeId><gtr:partnerContribution>To evaluate tissue samples from three distinct patient cohorts to identify in Hh protein expression or signalling within cancerous prostates.</gtr:partnerContribution><gtr:piContribution>Several biomarker studies designed to explore Hedgehog (Hh) signalling within distinct prostate cancer types or therapy groups have been completed. A cohort of 177 patients with pathological evidence of prostate cancer ranging from Gleason score 6 to Gleason score 9 (Gleason score is a known indicator of prostate cancer severity) has been generated. In addition, 60 transurethral resections of prostate were included (as a benign control) as well as 3 cell lines (PC3, LnCAP, RWPE). This is a post-surgical cohort where cancer patients underwent radical prostatectomy. About two third of the patients progressed to cure whilst the remaining patients required salvage radiotherapy or hormone treatment upon biochemical (PSA) relapse. This tumour tissue microarray is referred to as the Oxford Surgical TMA (OS-TMA). A further post-surgical cohort, taken from patients in Belgium, was also made. These patients (N=75) presented with advanced prostate tumours. This cohort is particularly interesting as nearly one half of its constituents featured primary tumours that metastasized to the lymph nodes following surgical intermission. 

The preliminary conclusions suggest that Hh pathway proteins may contribute to the advancement/severity of prostate cancer and that their expression potentially affects patient outcome following surgical intervention. The first post-surgical TMA was sliced and stained for 8 different proteins. 7/8 proteins tested showed significantly altered (+ or -) staining in cancer versus benign tissues. High epithelial staining intensity of 3 proteins (GLI1, SMO and SHH) tested on the OS-TMA were significantly associated with higher Gleason scores. Each protein is associated with an &amp;quot;activated&amp;quot; Hh pathway. Thus, the epithelial expression of Hh proteins GLI1, SMO, and SHH may contribute to relapse as a factor of their association with Gleason score. However, this hypothesis needs to be further validated.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>Dr Max Crispin: Antibody receptor refocusing: A technology for increasing the potency of therapeutic antibodies</gtr:description><gtr:id>49E302A5-03D5-4B4A-97E0-955384E23380</gtr:id><gtr:impact>The impact of EndoS on the efficiency of anti-HER24D5_8's ability to elicit antibody dependent cellular cytotoxicity (ADCC) against SKBr3 cells in competition with irrelevant serum antibodies has also begun. Pre-clinical efficacy studies have been initiated with using a humanised mouse model, HU-Murine. Extrapolating from our ex-vivo assays we expect that in the presence of Endo S, the therapeutic efficacy of anti-HER24D5_8 will be significantly enhanced. The potential for administration of EndoS at time points coinciding with peak serum anti-HER24D5_8 levels will also be explored.</gtr:impact><gtr:outcomeId>CFWq2YCjcWe-1</gtr:outcomeId><gtr:partnerContribution>To test this technology</gtr:partnerContribution><gtr:piContribution>We have tested the potential of EndoS technology in improving anti-cancer monoclonal efficacy. We successfully cloned and expressed the IgV region of TIM-4 and used this domain within a novel fluorescent adenoviral construct (Ad5-turboFP650, developed in our lab) to confirm PS binding ex-vivo using the human breast carcinoma cell line SKBr3 (Figure 1). We are now in the process of fusing this functional TIM-4 domain to IgG1 Fc in order to create an effector function competent (Fc-Fc?R) construct for EndoS testing. Once this construct is ready, we will test EndoS using the same adenoviral assay which contains an Fc-Fc?R engagement component. 
We have successfully expressed and isolated HER24D5/8 containing both normal (anti-HER24D5_8wt) and high mannose (anti-HER24D5_8HM) Fc glycosylation. The former is sensitive whilst the latter is resistant to EndoS mediated Fc-Fc?R disruption. Both of these antibodies recognise HER2 with near equivalent affinity as Herceptin (Genentech), the licensed variant of this monoclonal for use with HER2 positive breast cancer.
We have established a technique for the large scale purification of fully active EndoS from E.coli.
As a proof of concept, we have used this EndoS in conjunction with Herceptin using SKBr3 cells which overexpress HER2 (approximately 1 million copies per cell). Using our Ad5-turboFP650 assay we have demonstrated that EndoS pre-treatment effectively enhances Trastuzumab Fc?R engagement in the face of competition by irrelevant serum derived antibodies (Figure 4). Confirmation of this phenomenon is scheduled for anti-HER24D5_8wt and anti-HER24D5_8HM.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AIDS Clinical Trials Group (ACTG)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>AIDS Clinical Trials Group</gtr:description><gtr:id>9509CF81-B6EA-4E12-8B9A-2FDEE452656D</gtr:id><gtr:impact>Sharing of data - multidisciplinary - virology/immunology/epidemiology/mathematical modelliing</gtr:impact><gtr:outcomeId>58c159fdb4d326.22228410-1</gtr:outcomeId><gtr:partnerContribution>Monthly teleconferences to allow sharing of information and unpublished data to inform further research</gtr:partnerContribution><gtr:piContribution>UK representative of US ACTG HIV Cure strategy committee. Role is to explore new treatment strategies and studies, and to explore potential funding options.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford NIHR BRC Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FED9E414-C629-4560-BF28-B687A8B56DA2</gtr:id><gtr:impact>Schools and members of the public visited the stall over the course of the day - at least 100 visitors - to learn about HIV, its treatment and drug resistance.

Broad engagement across schools and general public.</gtr:impact><gtr:outcomeId>VsPQMuc3PxT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Exhibit at Science Museum, London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>932AD244-35EB-4FA3-A922-1DB0EB470A93</gtr:id><gtr:impact>Display at Science Museum in London on CHERUB, its research outputs and prospects for an HIV Cure</gtr:impact><gtr:outcomeId>56dc7c86841f81.05065053</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cherub.uk.net</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>09F75E4D-DEF3-42B5-AE30-F8D416EC3314</gtr:id><gtr:impact>Stand for NDM on HIV Cure at Cheltenham Science Festival</gtr:impact><gtr:outcomeId>56dc7cd66590f8.09573051</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.cherub.uk.net</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C7CDB001-D3BC-4F81-BD5B-DB863E9C81D0</gtr:id><gtr:impact>Lecture initiated questions on working in STEM subjects

Considerable interest from talented students to pursue career in research, particularly Oxford</gtr:impact><gtr:outcomeId>546352292773d8.70628286</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C7734158-3FD6-4EEC-AA60-2A46B4CF82EE</gtr:id><gtr:impact>Article in MRC Network Magazine - results not known

Impacts not known - article</gtr:impact><gtr:outcomeId>546351202c5153.72417284</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.mrc.ac.uk/news-events/publications/network-autumn-2014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A novel biomimetic tissue engineering scaffold for soft tissue repair (BioPatch)</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>S8457</gtr:fundingRef><gtr:id>8D5CBBEA-F42A-4555-BEBB-1F52B18BA07D</gtr:id><gtr:outcomeId>qyGkTsJrQLA</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247340</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Characterisation and targeting of myelodysplastic and leukemic stem cells</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>CFAD66C0-6F0B-4005-B4BE-6CD99ED67F3B</gtr:id><gtr:outcomeId>56d59a133ff4b1.78861405</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000000</gtr:amountPounds><gtr:country>Sweden, Kingdom of</gtr:country><gtr:currCode>SEK</gtr:currCode><gtr:currCountryCode>Sweden</gtr:currCountryCode><gtr:currLang>sv_SE</gtr:currLang><gtr:description>Tobias Award</gtr:description><gtr:fundingOrg>Tobias Foundation</gtr:fundingOrg><gtr:id>450468B2-0F22-4841-A4AB-721B3836AAE5</gtr:id><gtr:outcomeId>56bc96a850c1a1.85599958</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Swiss Anorexia Foundation : Biannual grant call : Additional funding for Pilot study of Deep Brain Stimulation for Severe Enduring Anorexia Nervosa</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Swiss Anorexia Nervosa Foundation</gtr:fundingOrg><gtr:id>8B4B3F0B-5133-4E44-B567-2B596087B7D4</gtr:id><gtr:outcomeId>58c55b713056e8.12368742</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>Ireland, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Muscular Dystrophy Ireland 2014</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy Ireland</gtr:fundingOrg><gtr:id>CDC199D2-9643-4877-B55E-2115B60DAEFE</gtr:id><gtr:outcomeId>56d9b6a024f284.47331351</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Donation to support the Pilot study of Deep Brain Stimulation in Severe Enduring Anorexia Nervosa</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Charles Wolfson Charitable Trust</gtr:fundingOrg><gtr:id>A9D42669-5B2B-42D0-8292-259F75C41953</gtr:id><gtr:outcomeId>58c55c1a6bd8d7.38966715</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>351146</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>The Bill and Melinda Gates Foundation project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1113647</gtr:fundingRef><gtr:id>3ADE0E63-DDBC-415B-99F0-87D111CAE2ED</gtr:id><gtr:outcomeId>56d07642a60523.57126724</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L00528X/1</gtr:fundingRef><gtr:id>F5CC01F3-ECFF-4097-A365-4D0A1A9D84B8</gtr:id><gtr:outcomeId>W6zwXHyDe9z</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Butterfield Awards for UK-Japan Collaboration in Medicine and Health 2015</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>The Great Britain Sasakawa Foundation</gtr:fundingOrg><gtr:id>E3C10774-54D0-4E66-8A5F-DB9FD0E8071B</gtr:id><gtr:outcomeId>56d9b777de2110.46714532</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Clinical Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L006588/1</gtr:fundingRef><gtr:id>AFDCB539-7C70-4104-BE3A-775CBFF7C013</gtr:id><gtr:outcomeId>54631f48b410b2.30720457</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Commission EHVA H2020</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>681032</gtr:fundingRef><gtr:id>424BDD48-3121-4861-ACBE-B272B26F8DDE</gtr:id><gtr:outcomeId>56cf139aeea550.56225840</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>111924</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>641317</gtr:fundingRef><gtr:id>9BF73A23-1CC1-4074-A206-BDD260F71ABA</gtr:id><gtr:outcomeId>56d85b956aeae7.01357916</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept Award (PI)</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>83C19FCF-A543-4250-B173-190E0B3E1496</gtr:id><gtr:outcomeId>56d5ab3109fd31.78850387</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2262504</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2021-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>104633/Z/14/Z</gtr:fundingRef><gtr:id>DE3DFAE6-DF53-4B65-94A1-F1016F15113C</gtr:id><gtr:outcomeId>56d85aee311268.67460481</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John Fell Fund</gtr:department><gtr:description>Acquisition of high-end FACS cell sorter for WIMM FACS facility.</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>EA392F4A-FC9F-4307-8990-1878269645B0</gtr:id><gtr:outcomeId>56bc97434c34d3.09601876</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The CiC award was to facilitate developement of a technology in which a patent application had already been made.</gtr:description><gtr:grantRef>MC_PC_12020</gtr:grantRef><gtr:id>5F8F02F9-02DB-4508-941D-9363806676F9</gtr:id><gtr:impact>The IP was assigned from ISIS Innovation to a new spin-out company Immago Biosystems Ltd. Immago has subsequently entered into a development agreement with a European pharmaceutical company.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56cf1260bb1664.41210962</gtr:outcomeId><gtr:patentId>WO 2013110946 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Combined therapeutic use of antibodies and endoglycosidases</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The data from this work will provide additional supporting data for two patent currently in prosecution:
&amp;quot;Antimicrobial compounds&amp;quot;, Y.-C. Jeong and M. G. Moloney, UK Patent Application No 1211203.3; Isis Innovation Limited, PCT application (2012).
&amp;quot;Antimicrobial compounds&amp;quot;, Y.-C. Jeong and M. G. Moloney, UK Patent Application No 1211202.5; Isis Innovation Limited, PCT application (2012).</gtr:description><gtr:grantRef>MC_PC_12020</gtr:grantRef><gtr:id>4626B14B-6AA8-4826-962C-8B96605B569B</gtr:id><gtr:impact>Possible spin out activity</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d46f65332c69.03688726</gtr:outcomeId><gtr:patentId>UK Patent Application No 1211203.3</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antibiotics</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We developed a method, based on immobilised exosomes, for diagnostic testing of autoantibodies against a broad range of cell surface proteins.</gtr:description><gtr:grantRef>MC_PC_12020</gtr:grantRef><gtr:id>3827D891-0DF6-494F-9859-2321E4D26378</gtr:id><gtr:impact>None yet, but this is still work in progress.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56cf4fc8599f84.65755425</gtr:outcomeId><gtr:patentId>14/899,523 (US application) and 14732605.1 - 1410 (European application)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method of detecting the presence or absence of autoantibodies</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Board of Center for Molecular Medicine, Karolinska Institutet</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2E327568-836D-4330-9531-D51F2B56DDC0</gtr:id><gtr:impact>Member of Board of Center for Molecular Medicine, Karolinska Institutet</gtr:impact><gtr:outcomeId>56d95edb7671f2.68394200</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International Society for Stem Cell Research (ISSCR) McEwen Award for Innovation selection committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>4ACA42E0-83B5-4573-AEE1-6B248C5AFC77</gtr:id><gtr:impact>International Society for Stem Cell Research (ISSCR) McEwen Award for Innovation selection committee</gtr:impact><gtr:outcomeId>56d96038e014d2.43728503</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.isscr.org</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chairman of Committee for allogeneic transplantations and cell therapies, Karolinska University Hospital</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7767516A-6925-4F4C-AF10-4D1B6A34E7DC</gtr:id><gtr:impact>Allogeneic transplantations and cell therapies.</gtr:impact><gtr:outcomeId>56d95f4a8466a8.84635231</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>New use of combination therapy of HDAC inhibitors plus vaccination in primary HIV infection as a strategy to cure HIV. Funded by &amp;pound;1.7 million MRC DCS award.</gtr:description><gtr:id>6934EB3D-4D6B-4A02-933E-CC30649218E5</gtr:id><gtr:impact>This combination of therapies is to be trialled in a clinical trial, with recruitment commencing in 2014</gtr:impact><gtr:outcomeId>gYEKotCRVLQ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HDACi + Vaccination for HIV cure</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Computer programme - deconvolutes mass spectra</gtr:description><gtr:id>9125D224-51C8-464C-94CF-1E7267F59D46</gtr:id><gtr:impact>Considerable uptake - more than 50 downloads</gtr:impact><gtr:outcomeId>56d8192711ce24.97677980</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UniDec</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>OX Stem Oncology</gtr:companyName><gtr:description>Establishment (as co-founder) of a spin-off company for development of targeting of cancer stem cells.</gtr:description><gtr:id>01559557-8BBB-445F-9785-E18D11E40FD4</gtr:id><gtr:impact>Development of therapeutic targeting of cancer stem cells.</gtr:impact><gtr:outcomeId>56e16ac42cc651.45742534</gtr:outcomeId><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Oxford Antibiotics</gtr:companyName><gtr:description>Antibacterial drug discovery</gtr:description><gtr:id>B9B49013-5B6E-4554-B3D0-1F8B380C3D66</gtr:id><gtr:impact>None at this stage (too early), but in active discussion with industry and investors to map future directions</gtr:impact><gtr:outcomeId>56d46fc291f844.21287627</gtr:outcomeId><gtr:yearCompanyFormed>2017</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Immago Biosystems Ltd</gtr:companyName><gtr:description>Immago is developing innovations in the field of therapeutic antibodies arising from work in the Glycobiology Institute of the University of Oxford.

With our technology we seek to enable a new generation of cancer therapies by enhancing the efficacy of therapeutic monoclonal antibodies (mAbs).

Working with partners, we aim to develop better anti-cancer therapies, by improving the efficacy of existing and abandoned mAbs, and developing novel mAbs taking advantage of our unique knowledge of the field of therapeutic glycoproteins.</gtr:description><gtr:id>3B009CD6-D07E-4FCD-A737-C7E7BBCA8D04</gtr:id><gtr:impact>Immago has entered into a development agreement with a European pharmaceutical company.</gtr:impact><gtr:outcomeId>56cf12e554a177.52205874</gtr:outcomeId><gtr:url>http://www.immago.co.uk/</gtr:url><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>22CFD24A-E9BC-468F-97A7-5B83B2E70ACA</gtr:id><gtr:title>Advancing the HIV cure agenda: the next 5 years.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>56dc5474c7d213.47009261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9170A34-27F4-4ABB-8BA8-7E072501AB52</gtr:id><gtr:title>Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nano letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3da82a2c3555614b11f8aa0ad48d123"><gtr:id>d3da82a2c3555614b11f8aa0ad48d123</gtr:id><gtr:otherNames>Ezzat K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1530-6984</gtr:issn><gtr:outcomeId>56d9b1ada2f355.78877943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E9CEE99-9E4B-4A5C-B9AA-64097710C4C6</gtr:id><gtr:title>Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678f61d9baba78039fd689d1985a666"><gtr:id>c678f61d9baba78039fd689d1985a666</gtr:id><gtr:otherNames>Woll PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>54513c2e975000.89223367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7D3E64-50E7-4728-ACE7-A8886738F2E9</gtr:id><gtr:title>Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56cf4857a854b8.39580922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56C7618F-CA5B-467F-B786-AAA01C30E0A2</gtr:id><gtr:title>Quantifying the stabilizing effects of protein-ligand interactions in the gas phase.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e51686fe545b10732e914a906cdf08a"><gtr:id>6e51686fe545b10732e914a906cdf08a</gtr:id><gtr:otherNames>Allison TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d8570341ebb6.05904869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF732807-9F25-4C8A-A83D-DC4861A31472</gtr:id><gtr:title>Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d064163ed626f319e23d5eff31b5e04d"><gtr:id>d064163ed626f319e23d5eff31b5e04d</gtr:id><gtr:otherNames>Gonnissen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5a8c06302692a7.45254710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26E2C786-1C7C-401B-A2C5-AA5D7FE52E7C</gtr:id><gtr:title>Gene expression profiles of changes underlying different-sized human rotator cuff tendon tears.</gtr:title><gtr:parentPublicationTitle>Journal of shoulder and elbow surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3023d572a8081eb596eb42c770ace2a8"><gtr:id>3023d572a8081eb596eb42c770ace2a8</gtr:id><gtr:otherNames>Chaudhury S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-2746</gtr:issn><gtr:outcomeId>58a56ac0e6a967.34388446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>120A823E-0021-447B-AB7F-7CA10700454E</gtr:id><gtr:title>H3K27ME3 DEMETHYLASES REGULATE IN VITRO CHONDROGENESIS AND CHONDROCYTE ACTIVITY IN OSTEOARTHRITIS</gtr:title><gtr:parentPublicationTitle>OSTEOARTHRITIS AND CARTILAGE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa12e2574f6921abed68e40be193fedf"><gtr:id>aa12e2574f6921abed68e40be193fedf</gtr:id><gtr:otherNames>Yapp C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1063-4584</gtr:issn><gtr:outcomeId>58a56a2d1fc505.03355002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>129608C3-51E2-4571-8C5E-08660BA24CA7</gtr:id><gtr:title>Investigations on recyclisation and hydrolysis in avibactam mediated serine ?-lactamase inhibition.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09e36c120da7c68a327600769ab29add"><gtr:id>09e36c120da7c68a327600769ab29add</gtr:id><gtr:otherNames>Choi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>589ae04fd3b408.61986621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>427A865D-D121-426D-8A3B-A5CF327CA0E4</gtr:id><gtr:title>Differential activation of the frontal pole to high vs low calorie foods: The neural basis of food preference in Anorexia Nervosa?</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef0d268d2a32e4de33689ad755e77bd0"><gtr:id>ef0d268d2a32e4de33689ad755e77bd0</gtr:id><gtr:otherNames>Scaife JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>58c5351c48ea47.60211410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDF6A055-5538-4C51-83B9-39D890E05CCC</gtr:id><gtr:title>A survey on beliefs and attitudes of trainee surgeons towards placebo.</gtr:title><gtr:parentPublicationTitle>BMC surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5443148f90d7d5f41f32f6fffbd8ef0"><gtr:id>b5443148f90d7d5f41f32f6fffbd8ef0</gtr:id><gtr:otherNames>Baldwin MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2482</gtr:issn><gtr:outcomeId>58a56ac28d59f3.61762525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D61087C-4D1C-4069-B617-C1989F932EFF</gtr:id><gtr:title>Feasibility of surgical randomised controlled trials with a placebo arm: a systematic review.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6fcc3df60bba17a8ae18a17fddae400"><gtr:id>b6fcc3df60bba17a8ae18a17fddae400</gtr:id><gtr:otherNames>Wartolowska K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58a56ac2c45140.77435315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3864D331-F2A7-4540-9770-EE8253E17C94</gtr:id><gtr:title>Charge reduction stabilizes intact membrane protein complexes for mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15800ff8a032bb59bb9fd8d1290eb798"><gtr:id>15800ff8a032bb59bb9fd8d1290eb798</gtr:id><gtr:otherNames>Mehmood S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>56d70035b3d1d2.37280459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06976335-168E-4A33-AD36-676C0F98990E</gtr:id><gtr:title>Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41658bddfcc110d6125b9bdb15823115"><gtr:id>41658bddfcc110d6125b9bdb15823115</gtr:id><gtr:otherNames>Echigoya Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5aa9345425e0a9.31009394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AE7268E-1EDE-40ED-A4E8-C272B737382C</gtr:id><gtr:title>Resorbable electrospun polydioxanone fibres modify the behaviour of cells from both healthy and diseased human tendons.</gtr:title><gtr:parentPublicationTitle>European cells &amp; materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf869d458af610e2de2a90c6b0015a18"><gtr:id>bf869d458af610e2de2a90c6b0015a18</gtr:id><gtr:otherNames>Kendal A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-2262</gtr:issn><gtr:outcomeId>58c65df9df43f4.34922908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03727738-C07A-4CA4-A7F8-7036EC39D11C</gtr:id><gtr:title>A comparative evaluation of the effect of polymer chemistry and fiber orientation on mesenchymal stem cell differentiation.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60743f838135004672703b1d4d98f90"><gtr:id>c60743f838135004672703b1d4d98f90</gtr:id><gtr:otherNames>Rowland DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-3296</gtr:issn><gtr:outcomeId>58a56ac12cd8a0.28330555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FB66108-BBFC-4D95-ACD7-12250F9F86A3</gtr:id><gtr:title>H3K27me3 demethylases regulate in vitro chondrogenesis and chondrocyte activity in osteoarthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6901191886018a99358f86d2f708defa"><gtr:id>6901191886018a99358f86d2f708defa</gtr:id><gtr:otherNames>Yapp C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>58a56ac24dc1f7.78918414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>577E2FE1-C67E-4A42-B226-36E2C71028F4</gtr:id><gtr:title>NMR-filtered virtual screening leads to non-metal chelating metallo-?-lactamase inhibitors.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07111f4196fe043435d46d8db76cbef8"><gtr:id>07111f4196fe043435d46d8db76cbef8</gtr:id><gtr:otherNames>Li GB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>58999febb710b1.28288856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32379D8F-6D1A-4FE8-939C-D406AA1613EA</gtr:id><gtr:title>The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d064163ed626f319e23d5eff31b5e04d"><gtr:id>d064163ed626f319e23d5eff31b5e04d</gtr:id><gtr:otherNames>Gonnissen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>58b6a9c25f5331.94505681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FBDC9C5-1977-46EE-8E98-C22ABB8DA10C</gtr:id><gtr:title>Dickkopf-3 is upregulated in osteoarthritis and has a chondroprotective role.</gtr:title><gtr:parentPublicationTitle>Osteoarthritis and cartilage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/688e1c764745aec0d9fd4c761052bef0"><gtr:id>688e1c764745aec0d9fd4c761052bef0</gtr:id><gtr:otherNames>Snelling SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1063-4584</gtr:issn><gtr:outcomeId>58a56a2cddd0b7.89690075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>872ADC76-5DA4-4D2A-97A8-2FFA9587E242</gtr:id><gtr:title>Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8edb4914b270217af9cc6d812470572"><gtr:id>f8edb4914b270217af9cc6d812470572</gtr:id><gtr:otherNames>Vasiljevic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>56cf1004abe879.84586317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A4AF234-147B-4384-BDCE-A63608900618</gtr:id><gtr:title>Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1728ccec91fe45aa3d33d427207f9037"><gtr:id>1728ccec91fe45aa3d33d427207f9037</gtr:id><gtr:otherNames>Lutz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>54513c2dc8d354.06241355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5AAF2F8-4144-4E94-BB34-85C8755D4422</gtr:id><gtr:title>Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d064163ed626f319e23d5eff31b5e04d"><gtr:id>d064163ed626f319e23d5eff31b5e04d</gtr:id><gtr:otherNames>Gonnissen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>5a7b1038663f46.17176780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D910CF8-AFB5-4F8B-BFCE-C60DBD113EE4</gtr:id><gtr:title>Effect of annealing on the mechanical properties and the degradation of electrospun polydioxanone filaments.</gtr:title><gtr:parentPublicationTitle>Journal of the mechanical behavior of biomedical materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efe5bda48f3143cceedfbf3a258d1c82"><gtr:id>efe5bda48f3143cceedfbf3a258d1c82</gtr:id><gtr:otherNames>Abhari RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1878-0180</gtr:issn><gtr:outcomeId>58c65dfab20252.72179896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55716485-1769-4B82-9374-92CECC90277E</gtr:id><gtr:title>The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.</gtr:title><gtr:parentPublicationTitle>Bone</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef6f5ebfd47716991d49cfa39cb8d11a"><gtr:id>ef6f5ebfd47716991d49cfa39cb8d11a</gtr:id><gtr:otherNames>Tsoumpra MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1873-2763</gtr:issn><gtr:outcomeId>56474593371be3.35398672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69CCA8CA-90F8-491E-9090-5BE8C6DA230B</gtr:id><gtr:title>Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9518a7f05163862ae602b67902c07daf"><gtr:id>9518a7f05163862ae602b67902c07daf</gtr:id><gtr:otherNames>Aoki Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_16371_21_23984357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0808CAB3-1EFA-4CC9-8F17-7B028246C38C</gtr:id><gtr:title>Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dcbcbb174ef85060f893c5185d2dbd0"><gtr:id>9dcbcbb174ef85060f893c5185d2dbd0</gtr:id><gtr:otherNames>Sanjuan-Pla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_16493_23_23934107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DCE157F-BB92-43D8-A9D8-409D16539426</gtr:id><gtr:title>Hungry for reward: How can neuroscience inform the development of treatment for Anorexia Nervosa?</gtr:title><gtr:parentPublicationTitle>Behaviour research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8abb0794fc531901bf63a91608cbbf5"><gtr:id>c8abb0794fc531901bf63a91608cbbf5</gtr:id><gtr:otherNames>Park RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0005-7967</gtr:issn><gtr:outcomeId>56d6f917ce3b29.04531433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD0A48EB-032C-4180-A471-47133A91B4D0</gtr:id><gtr:title>Evidence of insufficient quality of reporting in patent landscapes in the life sciences.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5740b47608c2a17faae775070e5702f3"><gtr:id>5740b47608c2a17faae775070e5702f3</gtr:id><gtr:otherNames>Smith JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>58c65d7527c6c3.93926956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D67DDF62-1A5E-4239-9D81-995B17008098</gtr:id><gtr:title>Reduced Resting-State Functional Connectivity in Current and Recovered Restrictive Anorexia Nervosa.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef0d268d2a32e4de33689ad755e77bd0"><gtr:id>ef0d268d2a32e4de33689ad755e77bd0</gtr:id><gtr:otherNames>Scaife JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>5a2fd635644750.59139113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AEA167D-91CF-4D0F-A5FE-332FF4DE548F</gtr:id><gtr:title>Comparison of transforming growth factor beta expression in healthy and diseased human tendon.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/933365c646af9ac22798f511412e0b78"><gtr:id>933365c646af9ac22798f511412e0b78</gtr:id><gtr:otherNames>Goodier HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>58a56ac30a8902.04045475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AD4E37F-57C2-40C8-8CFF-B0E7FAA0DDB4</gtr:id><gtr:title>Persistent stromal fibroblast activation is present in chronic tendinopathy.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8a783e67f3fe9432f840ccd1d01778c"><gtr:id>b8a783e67f3fe9432f840ccd1d01778c</gtr:id><gtr:otherNames>Dakin SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>58a56e3a711849.68557238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A01628E-62AE-409B-90F0-D7FEDE979F7F</gtr:id><gtr:title>A review of current surgical practice in the operative treatment of proximal humeral fractures: Does the PROFHER trial demonstrate a need for change?</gtr:title><gtr:parentPublicationTitle>Bone &amp; joint research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0dc882ffe7b38eee946a1bf6d6612dd"><gtr:id>b0dc882ffe7b38eee946a1bf6d6612dd</gtr:id><gtr:otherNames>Dean BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-3758</gtr:issn><gtr:outcomeId>58a56a2c9e61b0.02757674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8EA03D7-39DE-413B-BC87-10C431EABAEB</gtr:id><gtr:title>Maximising value from a United Kingdom Biomedical Research Centre: study protocol.</gtr:title><gtr:parentPublicationTitle>Health research policy and systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beed982914227a0221c1916225095a78"><gtr:id>beed982914227a0221c1916225095a78</gtr:id><gtr:otherNames>Greenhalgh T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1478-4505</gtr:issn><gtr:outcomeId>5a6f2da6bdae32.68748616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD80BA75-D052-4ACB-8E94-66AB3A1A81CA</gtr:id><gtr:title>A novel measure of compulsive food restriction in anorexia nervosa: validation of the Self-Starvation Scale (SS).</gtr:title><gtr:parentPublicationTitle>Eating behaviors</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6da6d13857b38395a48465a626a6575d"><gtr:id>6da6d13857b38395a48465a626a6575d</gtr:id><gtr:otherNames>Godier LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-0153</gtr:issn><gtr:outcomeId>56d6f95730f136.80545019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8886B70F-F16A-4C33-A900-9FC7AD5791BA</gtr:id><gtr:title>Biomimetic synthesis, antibacterial activity and structure-activity properties of the pyroglutamate core of oxazolomycin.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/795ee38f58bf97c64ce4b503f13f2998"><gtr:id>795ee38f58bf97c64ce4b503f13f2998</gtr:id><gtr:otherNames>Angelov P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>56d4743715dfc7.24079597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FE34645-F94E-4E65-89D9-2275A0EEE447</gtr:id><gtr:title>Impact of isolated germline JAK2V617I mutation on human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_16493_23_23535062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE32FB10-E063-4AF0-B56C-F4E204952252</gtr:id><gtr:title>Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56cf485d6d4c31.22466592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E00B5E-BE52-44BB-92D8-9891CF5AFD17</gtr:id><gtr:title>Characterization of single a-tracks by photoresist detection and AFM analysis-focus on biomedical science and technology.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57211aa66774a9287dec3e1a588d4212"><gtr:id>57211aa66774a9287dec3e1a588d4212</gtr:id><gtr:otherNames>Falzone N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>5464b8369d9d26.05640198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>557FC942-42CD-4D36-BFD9-439FB2371F01</gtr:id><gtr:title>The Effects of Glucocorticoid on Tendon and Tendon Derived Cells.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0dc882ffe7b38eee946a1bf6d6612dd"><gtr:id>b0dc882ffe7b38eee946a1bf6d6612dd</gtr:id><gtr:otherNames>Dean BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>58a56ac1608373.05566205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF3A7DEC-8C64-4116-A889-0BA13548856E</gtr:id><gtr:title>Past and projected temporal trends in arthroscopic hip surgery in England between 2002 and 2013.</gtr:title><gtr:parentPublicationTitle>BMJ open sport &amp; exercise medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5631dedc2427abc7e8fe281458752202"><gtr:id>5631dedc2427abc7e8fe281458752202</gtr:id><gtr:otherNames>Palmer AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2055-7647</gtr:issn><gtr:outcomeId>58a56ac33eeef9.13982443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C51764B-5625-4A7B-8AF2-DA56F42B47EA</gtr:id><gtr:title>Interaction of Avibactam with Class B Metallo-?-Lactamases.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de25d97265faf8f908a2a6c9c11892a"><gtr:id>6de25d97265faf8f908a2a6c9c11892a</gtr:id><gtr:otherNames>Abboud MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>581b5652530862.71165362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5003C407-33B1-4B7B-BCDD-2AFB7A3ED8F5</gtr:id><gtr:title>The road to avibactam: the first clinically useful non-?-lactam working somewhat like a ?-lactam.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3208f709bc1abed42116c259aef6b15"><gtr:id>e3208f709bc1abed42116c259aef6b15</gtr:id><gtr:otherNames>Wang DY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>5899e9f3366b75.00842244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C39A77AE-D1C5-48DD-9966-DAF836A843D3</gtr:id><gtr:title>Profibrotic mediators in tendon disease: a systematic review.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60f7a5c75d775c1dcf958e4502b67b91"><gtr:id>60f7a5c75d775c1dcf958e4502b67b91</gtr:id><gtr:otherNames>Morita W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>58a56ac21b6ed9.13337943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>886E01F9-9808-4A2E-8504-14B4D8171CB6</gtr:id><gtr:title>Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2107490ba1ae5f5dd21b0c1d4add91ca"><gtr:id>2107490ba1ae5f5dd21b0c1d4add91ca</gtr:id><gtr:otherNames>Calvopi?a K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>577d0e4bbcdb31.34600177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD5F623D-E4C7-43FF-BDEC-3779718075C7</gtr:id><gtr:title>The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d064163ed626f319e23d5eff31b5e04d"><gtr:id>d064163ed626f319e23d5eff31b5e04d</gtr:id><gtr:otherNames>Gonnissen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58b6a9034ff965.81902383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CDD6BC7-3559-45C2-AED2-694134B5BDBB</gtr:id><gtr:title>Compulsivity in anorexia nervosa: a transdiagnostic concept.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6da6d13857b38395a48465a626a6575d"><gtr:id>6da6d13857b38395a48465a626a6575d</gtr:id><gtr:otherNames>Godier LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-1078</gtr:issn><gtr:outcomeId>56d6f9575aecf8.68890488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC9D1736-9F15-4171-BEBB-F71A1041B00B</gtr:id><gtr:title>Scalar Cross-Relaxation Detected in the NOESY Spectra of Oxazolidines and Thiazolidines.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bce4f4599669dd632b39e1d3770594c2"><gtr:id>bce4f4599669dd632b39e1d3770594c2</gtr:id><gtr:otherNames>Panduwawala TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>58c66d151a9bb0.08167709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19904F52-117B-457C-8F61-D28D3445EE61</gtr:id><gtr:title>The magnitude and temporal changes of response in the placebo arm of surgical randomized controlled trials: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ba7152b364b7cf527e6722c90dd074"><gtr:id>d4ba7152b364b7cf527e6722c90dd074</gtr:id><gtr:otherNames>Wartolowska KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a56ac1c80eb6.09173604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D60E76EF-5619-4228-80B7-B27E855487CC</gtr:id><gtr:title>Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy.</gtr:title><gtr:parentPublicationTitle>Journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f23b43ba26fcbb438a326d7f723ba2ff"><gtr:id>f23b43ba26fcbb438a326d7f723ba2ff</gtr:id><gtr:otherNames>Nakamura A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1434-5161</gtr:issn><gtr:outcomeId>5aa93427421671.70291876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9102BA12-5D18-44CC-AA8D-C476660DEDA2</gtr:id><gtr:title>Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0faa31efcd24f8bdfa70eb424caae9"><gtr:id>9c0faa31efcd24f8bdfa70eb424caae9</gtr:id><gtr:otherNames>Dimitriou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58ac5e575ea494.76111003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B1925B3-2877-4D60-8C88-C18FC7E4ABE9</gtr:id><gtr:title>Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41658bddfcc110d6125b9bdb15823115"><gtr:id>41658bddfcc110d6125b9bdb15823115</gtr:id><gtr:otherNames>Echigoya Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d9b14ccf63a8.31959557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EC68F8D-A71F-4811-B3E8-15CAA656CBD1</gtr:id><gtr:title>Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/759aa1cc457edd8ac0338806c885a201"><gtr:id>759aa1cc457edd8ac0338806c885a201</gtr:id><gtr:otherNames>Miskew Nichols B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>5aa933aa1897a1.92735184</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F558FD3-E814-45AE-88E6-B959C8417D5E</gtr:id><gtr:title>Equisetin, reutericyclin and streptolodygin as natural product lead structures for novel antibiotic libraries.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71503d3d20249752779320683453a180"><gtr:id>71503d3d20249752779320683453a180</gtr:id><gtr:otherNames>Jeong YC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>56d4749a122777.51650265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79875CEF-F37E-46A2-840F-C74CF2CAE5F3</gtr:id><gtr:title>Mechanical properties of all-suture anchors for rotator cuff repair.</gtr:title><gtr:parentPublicationTitle>Bone &amp; joint research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31bcf41d2b8ff1213cf2a19b68674b0d"><gtr:id>31bcf41d2b8ff1213cf2a19b68674b0d</gtr:id><gtr:otherNames>Nagra NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2046-3758</gtr:issn><gtr:outcomeId>58a56e3a1f79e2.43390288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DDC0AC2-BB27-4A19-BCF6-88E67257D3CE</gtr:id><gtr:title>Insights into the Mechanistic Basis of Plasmid-Mediated Colistin Resistance from Crystal Structures of the Catalytic Domain of MCR-1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/befc58d95b309466ced570b65ae0e450"><gtr:id>befc58d95b309466ced570b65ae0e450</gtr:id><gtr:otherNames>Hinchliffe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>587f4525bef883.91282592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B956F498-4243-47AD-902A-3C533D7175D7</gtr:id><gtr:title>Antibacterial barbituric acid analogues inspired from natural 3-acyltetramic acids; synthesis, tautomerism and structure and physicochemical property-antibacterial activity relationships.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71503d3d20249752779320683453a180"><gtr:id>71503d3d20249752779320683453a180</gtr:id><gtr:otherNames>Jeong YC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>56d474373c8548.00798626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F869AD63-983A-43E5-8281-8DEEDA6200F2</gtr:id><gtr:title>The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c03e8311a8ae457e437dec1acb830623"><gtr:id>c03e8311a8ae457e437dec1acb830623</gtr:id><gtr:otherNames>Bayliss LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58c65dfa2f01c6.31299000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B10D0F09-343E-4E2D-B573-874D6C10CC4E</gtr:id><gtr:title>Deep Brain Stimulation in Anorexia Nervosa: Hope for the Hopeless or Exploitation of the Vulnerable? The Oxford Neuroethics Gold Standard Framework.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8abb0794fc531901bf63a91608cbbf5"><gtr:id>c8abb0794fc531901bf63a91608cbbf5</gtr:id><gtr:otherNames>Park RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>5a2fd6a6c7cb20.58330278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85479C51-AA21-4EF7-B5C8-A3AC5992E458</gtr:id><gtr:title>Emerging principles for the therapeutic exploitation of glycosylation.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cd83c5057556b4eae2e8e98fb547451"><gtr:id>9cd83c5057556b4eae2e8e98fb547451</gtr:id><gtr:otherNames>Dalziel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56cf1005208fa3.55469581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57CDA8F4-F9E8-4304-8EFB-5CCA63AE4BEC</gtr:id><gtr:title>Reduced Resting-State Functional Connectivity in Current and Recovered Restrictive Anorexia Nervosa.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef0d268d2a32e4de33689ad755e77bd0"><gtr:id>ef0d268d2a32e4de33689ad755e77bd0</gtr:id><gtr:otherNames>Scaife JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>58c539444161f1.97190843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>240F38F9-E579-43AE-BD7D-E20D99B26908</gtr:id><gtr:title>Translating Regenerative Biomaterials Into Clinical Practice.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5589413e17b3beb4e7da9e634d7124a1"><gtr:id>5589413e17b3beb4e7da9e634d7124a1</gtr:id><gtr:otherNames>Stace ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn><gtr:outcomeId>58a56ac1932e49.89401250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA85A929-2E10-4C62-806F-AE32646B2C9A</gtr:id><gtr:title>Structural and Biochemical Characterization of Rm3, a Subclass B3 Metallo-?-Lactamase Identified from a Functional Metagenomic Study.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efa19b74bcd8e6ddb3c47b9529ff96ee"><gtr:id>efa19b74bcd8e6ddb3c47b9529ff96ee</gtr:id><gtr:otherNames>Salimraj R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5899e9f3670582.88037651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AFB5355-0799-4DFD-8F97-A651C8953994</gtr:id><gtr:title>Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57211aa66774a9287dec3e1a588d4212"><gtr:id>57211aa66774a9287dec3e1a588d4212</gtr:id><gtr:otherNames>Falzone N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>56d5a44f2d1905.45816010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82EAC582-5248-4E63-91A1-9FA3682F7FB6</gtr:id><gtr:title>Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07383f1be695ee1c3e051f35970d41e2"><gtr:id>07383f1be695ee1c3e051f35970d41e2</gtr:id><gtr:otherNames>Schiffner T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56cb06f5096a93.25687079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DCE22C3-B67A-4112-9B12-0C043D50D5EA</gtr:id><gtr:title>Does compulsive behavior in Anorexia Nervosa resemble an addiction? A qualitative investigation.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6da6d13857b38395a48465a626a6575d"><gtr:id>6da6d13857b38395a48465a626a6575d</gtr:id><gtr:otherNames>Godier LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-1078</gtr:issn><gtr:outcomeId>56d6f957064ff5.90056552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA9A4707-EAEC-45F1-A90C-4013E08F4481</gtr:id><gtr:title>HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56cf48580990a5.89991529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F82209C4-1957-475F-874A-259FAE3D7F13</gtr:id><gtr:title>Membrane proteins bind lipids selectively to modulate their structure and function.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ecf32f01331b2e5eaeb0d56e5f21e27"><gtr:id>4ecf32f01331b2e5eaeb0d56e5f21e27</gtr:id><gtr:otherNames>Laganowsky A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56d8566181f337.76860858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4AC85C8-7CC1-4DBC-88EA-236D92B73A81</gtr:id><gtr:title>(8R,10aS)-Methyl 2,4-diamino-8-(tert-butyl)-6-oxo-6,8,10,10a-tetrahydrooxazolo[3'',4'':1',5']-pyrrolo[3',4':5,6]pyrido[2,3-d]pyrimidine-10a-carboxylate</gtr:title><gtr:parentPublicationTitle>Molbank</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5449c75a7c65184fda831375ad8cfbb"><gtr:id>f5449c75a7c65184fda831375ad8cfbb</gtr:id><gtr:otherNames>Clarke G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d4743761f941.75828329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE8F56A2-5245-46C6-8853-A6DBD8C1B1AF</gtr:id><gtr:title>Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c907488f14fd30f5bc6cabdea40dc8"><gtr:id>d7c907488f14fd30f5bc6cabdea40dc8</gtr:id><gtr:otherNames>Bardini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>54513c2e6709c3.32886569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBB388E3-87E2-4024-B174-98F3A299A27B</gtr:id><gtr:title>Fragments of bacterial endoglycosidase s and immunoglobulin g reveal subdomains of each that contribute to deglycosylation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4f81219c35e806a4b046dabdc6e934f"><gtr:id>d4f81219c35e806a4b046dabdc6e934f</gtr:id><gtr:otherNames>Dixon EV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56cf1004ec2fb1.06436199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F2FACB1-E77A-40AD-8658-6D6AB3E086C2</gtr:id><gtr:title>FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_16493_23_23727242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C23639C9-78BC-4333-A075-6645D3D115A4</gtr:id><gtr:title>Alpha and recoil track detection in poly(methyl methacrylate) (PMMA)--towards a method for in vitro assessment of radiopharmaceuticals internalized in cancer cells.</gtr:title><gtr:parentPublicationTitle>The Review of scientific instruments</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6254db9a4edf5340c711534092b8cf44"><gtr:id>6254db9a4edf5340c711534092b8cf44</gtr:id><gtr:otherNames>Myhra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0034-6748</gtr:issn><gtr:outcomeId>56d5a366497cb0.40842005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>712B8F9E-0BF0-4B21-AFCF-6AEA83744654</gtr:id><gtr:title>MAIT cells are activated during human viral infections.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd9c5d3ad67e5b8adc8f4409ebdea785"><gtr:id>fd9c5d3ad67e5b8adc8f4409ebdea785</gtr:id><gtr:otherNames>van Wilgenburg B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58b462a00b48b8.66559435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B6DBD7E-2A13-452A-92B6-CA53E563EB1A</gtr:id><gtr:title>Deep Brain Stimulation in Anorexia Nervosa: Hope for the Hopeless or Exploitation of the Vulnerable? The Oxford Neuroethics Gold Standard Framework.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8abb0794fc531901bf63a91608cbbf5"><gtr:id>c8abb0794fc531901bf63a91608cbbf5</gtr:id><gtr:otherNames>Park RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>58c5384e683e75.49029553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>590B6C77-53B4-4ECC-A6F0-137F95F8D2B7</gtr:id><gtr:title>Fused-Ring Oxazolopyrrolopyridopyrimidine Systems with Gram-Negative Activity.</gtr:title><gtr:parentPublicationTitle>Antibiotics (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2079-6382</gtr:issn><gtr:outcomeId>58c66d52cf1176.75611543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BF26A18-A39B-4FC0-80B5-B8A2743E254A</gtr:id><gtr:title>Effectiveness of open and arthroscopic rotator cuff repair (UKUFF): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The bone &amp; joint journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cba5f699b7a3ce461fdf862f3e576e71"><gtr:id>cba5f699b7a3ce461fdf862f3e576e71</gtr:id><gtr:otherNames>Carr A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2049-4394</gtr:issn><gtr:outcomeId>58c65dfa67f228.57435997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0C67BDD-3B43-4734-90B9-09771CA837AB</gtr:id><gtr:title>Spatial distribution of Auger electrons emitted from internalised radionuclides in cancer cells: the photoresist autoradiography (PAR) method.</gtr:title><gtr:parentPublicationTitle>Radiation protection dosimetry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae575a7e051ac4adba2801232a26756"><gtr:id>4ae575a7e051ac4adba2801232a26756</gtr:id><gtr:otherNames>Royle G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0144-8420</gtr:issn><gtr:outcomeId>56559512dd7054.42242369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E6484B1-0AD1-40F1-BE22-4B2E0A4C40AD</gtr:id><gtr:title>Germline JAK2 mutation in a family with hereditary thrombocytosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_16493_23_22397670</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12020</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>